Blood Eosinophil Count as a Predictive Biomarker of Chronic Obstructive Pulmonary Disease Exacerbation in a Real-World Setting

Table 2

Comparison of therapies between nonexacerbators and exacerbators.

	Nonexacerbators (n = 249)	Exacerbators (n = 22)	value
Component included
ICS	89 (36%)	13 (59%)	0.028
LABA	197 (79%)	22 (100%)	0.007
LAMA	179 (72%)	14 (64%)	0.277
Inhalation therapy
ICS mono	1 (0.4%)	0 (0%)	0.919
LABA mono	22 (9%)	4 (18%)	0.146
LAMA mono	31 (12%)	0 (0%)	0.061
ICS + LABA	29 (12%)	4 (18%)	0.272
LAMA + LABA	89 (36%)	5 (23%)	0.160
ICS + LABA + LAMA	57 (23%)	9 (41%)	0.057
Others
Macrolide	32 (13%)	5 (23%)	0.164
Theophylline	23 (9%)	5 (23%)	0.061
LTRA	18 (7%)	6 (27%)	0.007
HOT	24 (10%)	9 (41%)	<0.001

Note. Data are shown as number of patients (percentage). Significant differences are marked using bold font. Macrolide and LTRA were administered orally. ICS, inhaled corticosteroid; LABA, long-acting β²-agonist; LAMA, long-acting muscarinic antagonist; LTRA, leukotriene receptor antagonist; HOT, home oxygen therapy.